VYNE Therapeutics (VYNE) Operating Income (2017 - 2026)
VYNE Therapeutics (VYNE) posted Operating Income of -$3.8 million for Q1 2026, up 49.4% on a QoQ basis from -$7.5 million in Q2 2025, and up 58.51% year-over-year from -$2.4 million in Q1 2025.
VYNE Therapeutics (VYNE) Operating Income (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Operating Income history runs 10 years deep, the most recent figure standing at -$3.8 million for Q1 2026.
- Quarterly Operating Income rose 58.51% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.3 million (up 26.68% YoY) and the FY2025 annual result came in at -$29.7 million, up 31.83% from the prior year.
- Operating Income was -$3.8 million for Q1 2026 at VYNE Therapeutics, up from -$7.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$3.8 million in Q1 2026 and bottomed at -$13.1 million in Q3 2024.
- A 5-year average of -$8.5 million and a median of -$8.3 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income slumped 109.99% — and 2026, when it surged 58.51%.
- VYNE Therapeutics' Operating Income stood at -$8.0 million in 2022, then grew by 14.43% to -$6.8 million in 2023, then sank by 86.91% to -$12.8 million in 2024, then soared by 40.94% to -$7.5 million in 2025, then jumped by 49.4% to -$3.8 million in 2026.
- Business Quant data shows VYNE's Operating Income at -$3.8 million in Q1 2026, -$7.5 million in Q2 2025, and -$9.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -445.22 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.82 Mn |
| Jun 30, 2025 | -7.54 Mn |
| Mar 31, 2025 | -9.20 Mn |
| Dec 31, 2024 | -12.77 Mn |
| Sep 30, 2024 | -13.09 Mn |
| Jun 30, 2024 | -10.40 Mn |
| Mar 31, 2024 | -7.38 Mn |
| Dec 31, 2023 | -6.83 Mn |
| Sep 30, 2023 | -6.23 Mn |
| Jun 30, 2023 | -10.32 Mn |
| Mar 31, 2023 | -5.88 Mn |
| Dec 31, 2022 | -7.98 Mn |
| Sep 30, 2022 | -9.33 Mn |
| Jun 30, 2022 | -8.29 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.85 Mn |
| Sep 30, 2021 | -10.77 Mn |
| Jun 30, 2021 | -9.54 Mn |
| Mar 31, 2021 | -9.76 Mn |
| Dec 31, 2020 | -21.99 Mn |